We treated the rat pancreatic carcinoma cell line BSp73ASs6 that highly expresses CD44v6 with v6‐PEG and tested whether this treatment impacted HGF‐induced activation of the RTK Met and its downstream target, Erk. The gene discussed is MET; the disease is exocrine pancreatic carcinoma.